Raj Chakraborty (@rajshekharucms) ranks #4 among US multiple myeloma KOLs on X in 2026, by engagement from fellow physicians. 63 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: CARTITUDE-4, MajesTEC-3, MajesTEC-9. CMS Open Payments lists $13,214 in 2025 general payments.
At a Glance
- 14 posts naming a trial since ASH 2025
- 9 trials discussed by name
- Multiple Myeloma: US #4, Global #4 · 63 physicians engaged
- Leading physician voice: #2 of 9 physicians on CARTITUDE-4; #2 of 3 physicians on iMMagine-1
- Presented at ASH 2025 in 2026
- CMS Open Payments lists $13,214 in 2025 general payments.
This Month
What Raj Chakraborty has posted in the last 30 days. Updated November 11, 2026.
No trial posts in the last 30 days.
Who Amplifies Raj Chakraborty
Physicians who reposted Raj Chakraborty’s trial posts most often since ASH 2025.
2026 Rankings
| List | US rank | Global rank | Peer Engagement Score | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|---|
| Multiple Myeloma | #4 | #4 | 76/100 | 63 | 94 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Raj Chakraborty presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- ASH 2025 · OralEtentamig in relapsed/refractory AL amyloidosisSource: @HadidiSamer on X ↗
What Colleagues Are Saying About Raj Chakraborty
2026 posts by fellow physicians that mention @rajshekharucms, quoted word for word.
#ASH25 #mmsm @ASH_hematology Oral-amyloidosis Etentamig @rajshekharucms R/R AL amyloidosis, patients characteristics https://t.co/1PKqc7cH02
Trials Raj Chakraborty Discussed since ASH 2025
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| CARTITUDE-4 | 3 | #2 of 9 | Jul 24, 2026 |
| MajesTEC-3 | 3 | #8 of 15 | May 30, 2026 |
| MajesTEC-9 | 3 | #4 of 16 | May 29, 2026 |
| LimiTec | 3 | — | Dec 8, 2025 |
| MajesTEC-5 | 1 | #3 of 6 | Oct 10, 2026 |
| SUCCESSOR-2 | 1 | #12 of 15 | May 25, 2026 |
| inMMyCAR | 1 | #6 of 6 | May 25, 2026 |
| TECLISITO | 1 | — | Dec 4, 2025 |
| iMMagine-1 | 1 | #2 of 3 | Nov 28, 2025 |
Raj Chakraborty on CARTITUDE-4
With all the advances in relapsed #MultipleMyeloma in the past one year (from CARTITUDE-4 to TEC-3/9 and now TAL-6), it has become impossible to open RCTs in the 1-3 prior line space without CAR T/BsAb in the control arm (at least in the US). With not only PFS but also OS benefit
@Phhersh @NEJM @TheLancet Ok, I see your point. Yes, agree with that. With just 18 months median follow-up, I wouldn’t put much weight on the tail here (it’s a “fairy tail” as @VPrasadMDMPH would say haha). The median follow-up up is almost double in MajesTEC-3 and CARTITUDE-4, for example. Will have to
With 85% CD38-refractory, we are seeing at least a similar (if not better) PFS with single-agent Teclistamab when compared to Cilta-cel arm of CARTITUDE-4, which had just ~25% CD38-refractory. These results, along with MajesTEC-3, challenge the dogma of “CAR T before BsAbs” in https://t.co/D5kF3Igr8X
Raj Chakraborty on MajesTEC-3
@Phhersh @NEJM @TheLancet Ok, I see your point. Yes, agree with that. With just 18 months median follow-up, I wouldn’t put much weight on the tail here (it’s a “fairy tail” as @VPrasadMDMPH would say haha). The median follow-up up is almost double in MajesTEC-3 and CARTITUDE-4, for example. Will have to
With 85% CD38-refractory, we are seeing at least a similar (if not better) PFS with single-agent Teclistamab when compared to Cilta-cel arm of CARTITUDE-4, which had just ~25% CD38-refractory. These results, along with MajesTEC-3, challenge the dogma of “CAR T before BsAbs” in https://t.co/D5kF3Igr8X
1. MAJESTEC-3 [Tec-Dara vs DPd/DVd]: 1-3 prior LoT including a PI and lenalidomide; prior anti-CD38 exposure permitted (refractory not allowed). Topline results: PFS HR 0.17(!!) and OS HR 0.46 favoring Tec-Dara, with 3-year PFS 83% in Tec-Dara arm! MRD-neg rate (10^-5; NGS)
Raj Chakraborty on MajesTEC-9
MajesTEC-9 is now out in @NEJM! 18-month PFS ~70% and DoR~80% with Tec! Infection risk mostly front-loaded (1st 6 months) but doesn't plateau [G3+ infections remains at ~10% in each time window beyond 12 months]. The slope of PFS curve in Tec arms progressively flattens with https://t.co/AnDlG0vEjw https://t.co/cAHsfF2a2a
1. MajesTEC-9 [Tec vs PVd/Kd]: Single-agent Tec decimated PVd/Kd in a population that was 80% anti-CD38-refrcatory and 85% Len-refractory, with a PFS HR of 0.29 and OS HR of 0.6. While the trial should have ideally allowed crossover to Tec in the control arm, ~70% ended up
MajesTEC-9 with both PFS and OS benefit of Teclistamab monotherapy versus PVD/Kd (in a population 100% Dara and Len-exposed)! We finally will have a great (non-CAR T) option for relapse post frontline Dara-(V)Rd, especially in patients relapsing on continuous Dara-R! Will there
Raj Chakraborty on LimiTec
We need a “LimiTEC” for every indefinite BsAb regimen! #ASH25 https://t.co/WmsbWIPdus
Love #LessIsMore trials like TECLISito and LimiTEC! #ASH25 https://t.co/BH4fk1rhAT
3. LimiTec Trial: Prospective study of Tec discontinuation after 6-9 months of therapy in patients achieving >=VGPR (BMBx/MRD assessment not required): n=43 with 4 prior LoT, 95% TCR, 44% penta-refractory, 23% with prior BCMA-DT. Median f/u ~11 months. Failure-Free Probability
Raj Chakraborty on MajesTEC-5
I am surprised to see the results here and was expecting that >90% of respondents would pick the first option (<5%). As BCMA BsAbs continue to show superior PFS and OS in multiple RCTs in earlier lines of therapy and 100% MRD-neg rate in frontline (MajesTEC-5; TecLille), we have https://t.co/AnonHpJIKW
Raj Chakraborty on SUCCESSOR-2
5. SUCCESSOR-2 RCT [Mezi-Kd vs Kd] in R/R #MultipleMyeloma: Abstract not released yet, but will likely be a potential non-CAR/BsAb option for CD38-refractory patients.
Raj Chakraborty on inMMyCAR
6. Updated results from inMMyCAR [in vivo BCMA CAR T-cell therapy]: Median time from consent to infusion ~2 weeks! 6/6 patients MRD-negative [all but one at 10^-6]. No ICANS/DNTs observed yet. 1 patients with EMD had complete resolution by 1 month. My take: Exciting results,
Raj Chakraborty on TECLISITO
Love #LessIsMore trials like TECLISito and LimiTEC! #ASH25 https://t.co/BH4fk1rhAT
Raj Chakraborty’s Most-Engaged Posts since ASH 2025
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Incredible 2-year PFS with Ramantamig in a ~95% CD38-refractory and 100% triple-class exposed population! These results are substantially superior compared to single-agent BCMA BsAbs and BCMA or GPRC5D CAR Ts in similar population. Based on these results, its plausible that we https://t.co/ee0o5VrzHW
🔥Just in time for #ASH25, our open access paper @AjHematology on why we DON'T routinely recommend treatment in high-risk SMM (yet) is now online! @MorieGertz https://t.co/eKzjWr3MWr I encourage patients & trainees to listen to the best arguments on both sides of the debate! https://t.co/hs1vcjsEx1
Game-Changer! The plateau is hard to beat. With universal IVIG prophylaxis, these results could be event better by averting the early infection-related deaths, which would have potentially pushed the 3-year PFS beyond 90%! Now awaiting MajesTEC-9 to see how much single-agent Tec https://t.co/blUwQCwtWy
Wow! These curves in 1 and 2+ HRCA are amazing! In patients who are CD38 naive or exposed (not refractory), based on these data, I would recommend Tec-Dara over Cilta-cel in both standard-risk and high-risk! For patients who are CD38-refractory, both Cilta-cel and Tec https://t.co/A8QX2XjpsW
We really enjoyed this back and forth regarding the future of Cilta-Cel in #MultipleMyeloma and I believe it brought the best arguments on both sides. @NicoGagelmann @ManniMD1 @Eddie_Cliff https://t.co/HVIgc4btFg
Industry Payments
CMS Open Payments · 2025 general payments
$13,214 across 28 payments